Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients

Transplantation

Volumn 93, Issue 3, 2012, Pages 319-324

  Morrow, William Robert ^a   Frazier, Elizabeth A ^a   Mahle, William T ^b   Harville, Terry O ^a   Pye, Sherry E ^a   Knecht, Kenneth R ^a   Howard, Emily L ^a   Neal Smith, R ^c   Saylors, Robert L ^a   Garcia, Xiomara ^a   Jaquiss, Robert D B ^d   Woodle, E Steve ^e  

^a ARKANSAS CHILDREN S HOSPITAL   (United States)

^b SIBLEY HEART CENTER CARDIOLOGY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Antibody mediated rejection; Donor specific antibodies; Pediatric heart transplant

Indexed keywords

ANTIBODY; BORTEZOMIB; COMPLEMENT COMPONENT C4D; CYCLOPHOSPHAMIDE; DOUBLE SPECIFIC ANTIBODY; HLA ANTIGEN ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LYMPHOCYTE ANTIBODY; PROTEIN ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ANTIBODY MEDIATED REJECTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGENICITY; ARTICLE; BLOOD GROUP TYPING; CARDIAC GRAFT REJECTION; CASE REPORT; CHILD; CONTROLLED STUDY; DRUG EFFICACY; GRAFT RECIPIENT; HEART FUNCTION; HEART TRANSPLANTATION; HEMODYNAMICS; HUMAN; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PEDIATRICS; PLASMAPHERESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; BORONIC ACIDS; CHILD; GRAFT REJECTION; HEART TRANSPLANTATION; HLA ANTIGENS; HUMANS; INFANT; ISOANTIBODIES; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RETROSPECTIVE STUDIES; TISSUE DONORS;

EID: 84856439102     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31823f7eea     Document Type: Article

References (37)

1. Velez M, Johnson MR. Management of allosensitized cardiac transplant candidates. Transplant Rev 2009; 23: 235.
2. Rose EA, Smith CR, Petrossian GA, et al. Humoral immune responses after cardiac transplantation: Correlation with fatal rejection and graft atherosclerosis. Surgery 1989; 106: 203.
3. Lavee J, Kormos RL, Duquesnoy RJ, et al. Influence of panel-reactive antibody and lymphocytoxic crossmatch on survival after heart transplantation. J Heart Lung Transplant 1991; 10: 921.
4. Smith JD, Danskine AJ, Laylor RM, et al. The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation. Transplant Immunol 1993; 1: 60.
5. Wright EJ, Fiser WP, Edens E, et al. Cardiac transplant outcomes in pediatric patients with pre-formed anti-human leukocyte antigen antibodies and/or positive retrospective crossmatch. J Heart Lung Transplant 2007; 26: 1163.
6. Holt DB, Lublin DM, Phelan DL, et al. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing per-operative plasmapheresis and cytolytic therapy. J Heart Lung Transplant 2007; 26: 876.
7. Goffinet J, St Pierre Schneider B. Preformed anti-human leukocyte antigen antibodies jeopardize cardiac transplantation in patients with a left ventricular assist device. Heart Lung 2002; 31: 122.
8. McKenna DH, Eastlund T, Segall M, et al. HLA alloimmunization in patients requiring ventricular assist device support. J Heart Lung Transplant 2002; 21: 1218.
9. Kfoury AG, Hammond ME, Snow GL, et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibodymediated or stable mixed cellular and antibody-mediated rejection. J Heart Lung Transplant 2009; 28: 781.
10. Feingold B, Bowman P, Zeevi A, et al. Survival in allosensitized children after listing for cardiac transplantation. J Heart Lung Transplant 2007; 26: 565.
11. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: Risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22: 58.
12. Taylor DO, Yowell RL, Kfoury AG, et al. Allograft coronary artery disease: Clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant 2000; 19: 518.
13. Soleimani B, Lechler RI, Hornick PI, et al. Role of alloantibodies in the pathogenesis of graft arteriosclerosis in cardiac transplantation. Am J Transplant 2006; 6: 1781.
14. Rose ML. De novo production of antibodies after heart or lung transplantation should be regarded as an early warning system. J Heart Lung Transplant 2004; 23: 385.
15. Xydas S, Yang JK, Burke EM, et al. Utility of post-transplant anti-HLA antibody measurements in pediatric cardiac transplant recipients. J Heart Lung Transplant 2005; 24: 1289.
16. Ratkovec RM, Hammond EH, O'Connell JB, et al. Outcome of cardiac transplant recipients with a positive donor-specific crossmatch- Preliminary results with plasmapheresis. Transplantation 1992; 54: 651.
17. Wang SS, Chou NK, Ko WJ, et al. Effect of plasmapheresis for acute humoral rejection after heart transplantation. Transplant Proc 2006; 38: 3692.
18. Grauhan O, Knosalla C, Ewert R, et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. J Heart Lung Transplant 2001; 20: 316.
19. Pisani BA, Mullen GM, Malinowska K, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 1999; 18: 701.
20. Jacobs JP, Quintessenza JA, Boucek RJ, et al. Pediatric cardiac transplantation in children with high panel reactive antibody. Ann Thorac Surg 2004; 78: 1703.
21. Baran DA, Lubitz S, Alvi S, et al. Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab. Transplant Proc 2004; 36: 3164.
22. Garrett HE, Duvall-Seaman D, Helsley B, et al. Treatment of vascular rejection with rituximab in cardiac transplantation. J Heart Lung Transplant 2005; 24: 337.
23. Balfour IC, Fiore A, Graff RJ, et al. Use of rituximab to decrease panelreactive antibodies. J Heart Lung Transplant 2005; 24: 628.
24. Everly J, Walsh RC, Alloway RR, et al. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant 2009; 14: 662.
25. Perry DJ, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201.
26. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody and cell mediated acute rejection. Transplantation 2008; 86: 1754.
27. Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor-based primary therapy for antibody mediated renal allograft rejection. Transplantation 2010; 89: 277.
28. Smith RN, Brousaides N, Grazette L, et al. C4d deposition in cardiac allografts correlates with alloantibody. J Heart Lung Transplant 2005; 24: 1202.
29. Lones MA, Czer LS, Trento A, et al. Clinical-pathologic features of humoral rejection in cardiac allografts: A study in 81 consecutive patients. J Heart Lung Transplant 1995; 14: 151.
30. Harville TO. Use of immunoglobulins in rheumatologic disorders and autoimmunopathies. In: Wahn V, Orange J eds. Clinical use of immunoglobulins. Bremen, London, Boston, UNI-MED Verlag AG 2008, pp 127.
31. Harville TO. HLA typing for cellular product characterization and identity testing. In: Areman EM, Loper K, eds. Cellular therapy: Principles, methods, and regulations. Bethesda, MD, AABB 2009, pp 627.
32. Walsh RC, Shields AR, Brailey P, et al. Prospective safety and efficacy analysis of bortezomib-based therapy for desensitization of sensitized kidney transplant candidates. Am J Transplant 2010; 10: 44.
33. Taylor C. Back to the future: Applications of contemporary technology to long standing questions about the clinical relevance of human leukocyte antigen specific allo-antibodies in renal transplantation. Human Immunol 2009; 70: 563.
34. Reed EF, Demetris AJ, Hammond E, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006; 25: 153.
35. Woodle ES, Light J, Rubin M, et al. Proteasome inhibitor therapy for antibody mediated rejection: Initial report from a multicenter collaborative. Am J Transplant 2010; 10(suppl 4): 83.
36. Horton TM, Pati D, Plon SE, et al. A phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: A children's oncology group study. Clin Cancer Res 2007; 13: 1516.
37. Blaney SM, Bernstein M, Neville K, et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: A children's oncology group study (ADVL0015). J Clin Oncol 2004; 22: 4804.